TCTR20240318001已完成3 期
A Randomized Double-blind, Placebo-Controlled Study on Evaluating the Efficacy of Hair Serum Containing Solid Lipid Nanoparticle Loaded Acanthus ebracteatus Vahl. Extract in Androgenic Alopecia
aresuan University0 个研究点目标入组 72 人开始时间: 2024年3月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •The volunteers, recruited in the study, are healthy male with 20-55 years old with Hamilton Norwood types 2 to 5 of androgenic alopecia.
排除标准
- •They are also excluded if they have had or used 1. topical minoxidil within the
- •previous 6 months, 2. topical botanicals/nutraceuticals for hair regrowth within the
- •previous 3 months, 3. oral 5alpha-reductase inhibitors, oral retinoids, radiation to the scalp,
- •or chemotherapy within the previous12 months, 4. systemic steroids for more than 14
- •days within 2 months of enrollment, 5. stage 6 to 7 androgenic alopecia, 6. men with a
- •history of hair transplant, scalp reduction, or hair weaves as well as uncontrolled
- •hypertension, or untreated prostate cancer.
研究者
相似试验
已完成
3 期
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer ( MONALEESA 3)C50.9Advanced Breast Canceradvanced breast cancerLBCTR2019080232ovartis Pharma Services Inc.6
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-ITGENFIT150
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-FRGENFIT150
招募中
3 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidPrimary Biliary Cholangitis2024-512232-30-00Ipsen Pharma61
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 10019805 - Hepatobiliary disordersPrimary Biliary CholangitisEUCTR2019-004941-34-DEIPSEN Pharma SAS161